130 related articles for article (PubMed ID: 32732877)
1. Quality of life analysis after stereotactic radiofrequency ablation of liver tumors.
Schullian P; Gertl A; Laimer G; Putzer D; Siebert U; Levy E; Bale R
Sci Rep; 2020 Jul; 10(1):12809. PubMed ID: 32732877
[TBL] [Abstract][Full Text] [Related]
2. Stereotactic radiofrequency ablation (SRFA) for recurrent colorectal liver metastases after hepatic resection.
Schullian P; Johnston EW; Putzer D; Laimer G; Waroschitz G; Braunwarth E; Amann A; Maglione M; Bale R
Eur J Surg Oncol; 2021 Apr; 47(4):866-873. PubMed ID: 33032865
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic radiofrequency ablation as first-line treatment of recurrent HCC following hepatic resection.
Schullian P; Laimer G; Putzer D; Levy E; Braunwarth E; Stättner S; Bale R
Eur J Surg Oncol; 2020 Aug; 46(8):1503-1509. PubMed ID: 32222261
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic Radiofrequency Ablation of Breast Cancer Liver Metastases: Short- and Long-Term Results with Predicting Factors for Survival.
Schullian P; Johnston E; Laimer G; Putzer D; Eberle G; Scharll Y; Ianetti-Hackl C; Bale R
Cardiovasc Intervent Radiol; 2021 Aug; 44(8):1184-1193. PubMed ID: 33825059
[TBL] [Abstract][Full Text] [Related]
5. Percutaneous stereotactic radiofrequency ablation of colorectal liver metastases.
Bale R; Widmann G; Schullian P; Haidu M; Pall G; Klaus A; Weiss H; Biebl M; Margreiter R
Eur Radiol; 2012 Apr; 22(4):930-7. PubMed ID: 22071776
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic radiofrequency ablation of subcardiac hepatocellular carcinoma: a case-control study.
Schullian P; Johnston EW; Putzer D; Eberle G; Laimer G; Bale R
Int J Hyperthermia; 2019; 36(1):876-885. PubMed ID: 31462110
[No Abstract] [Full Text] [Related]
7. Safety and efficacy of stereotactic radiofrequency ablation for very large (≥8 cm) primary and metastatic liver tumors.
Schullian P; Johnston EW; Putzer D; Eberle G; Laimer G; Bale R
Sci Rep; 2020 Jan; 10(1):1618. PubMed ID: 32005871
[TBL] [Abstract][Full Text] [Related]
8. Feasibility, safety, and long-term efficacy of stereotactic radiofrequency ablation for tumors adjacent to the diaphragm in the hepatic dome: a case-control study.
Schullian P; Putzer D; Laimer G; Levy E; Bale R
Eur Radiol; 2020 Feb; 30(2):950-960. PubMed ID: 31489472
[TBL] [Abstract][Full Text] [Related]
9. Stereotactic radiofrequency ablation of a variety of liver masses in children.
Hetzer B; Vogel GF; Entenmann A; Heil M; Schullian P; Putzer D; Meister B; Crazzolara R; Kropshofer G; Salvador C; Straub S; Karall D; Niederwanger C; Cortina G; Janecke A; Freund-Unsinn K; Maurer K; Schweigmann G; Oberhuber G; Renz O; Schneeberger S; Müller T; Bale R
Int J Hyperthermia; 2020; 37(1):1074-1081. PubMed ID: 32954876
[TBL] [Abstract][Full Text] [Related]
10. Stereotactic radiofrequency ablation (SRFA) of liver lesions: technique effectiveness, safety, and interoperator performance.
Widmann G; Schullian P; Haidu M; Bale R
Cardiovasc Intervent Radiol; 2012 Jun; 35(3):570-80. PubMed ID: 21671150
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic radiofrequency ablation of unresectable intrahepatic cholangiocarcinomas: a retrospective study.
Haidu M; Dobrozemsky G; Schullian P; Widmann G; Klaus A; Weiss H; Margreiter R; Bale R
Cardiovasc Intervent Radiol; 2012 Oct; 35(5):1074-82. PubMed ID: 22006031
[TBL] [Abstract][Full Text] [Related]
12. Quality of Life in Papillary Thyroid Microcarcinoma Patients Undergoing Radiofrequency Ablation or Surgery: A Comparative Study.
Lan Y; Luo Y; Zhang M; Jin Z; Xiao J; Yan L; Zhu Y
Front Endocrinol (Lausanne); 2020; 11():249. PubMed ID: 32499754
[No Abstract] [Full Text] [Related]
13. Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study.
Ren Y; Cao Y; Ma H; Kan X; Zhou C; Liu J; Shi Q; Feng G; Xiong B; Zheng C
BMC Cancer; 2019 Oct; 19(1):983. PubMed ID: 31640620
[TBL] [Abstract][Full Text] [Related]
14. Health-related quality of life of patients with intermediate hepatocellular carcinoma after liver resection or transcatheter arterial chemoembolization.
Xie ZR; Luo YL; Xiao FM; Liu Q; Ma Y
Asian Pac J Cancer Prev; 2015; 16(10):4451-6. PubMed ID: 26028113
[TBL] [Abstract][Full Text] [Related]
15. Transarterial Chemoembolization Followed by Radiofrequency Ablation for Hepatocellular Carcinoma: Impact of the Time Interval between the Two Treatments on Outcome.
Liu D; Liu M; Su L; Wang Y; Zhang X; Long H; Kuang M; Xie X; Lin M
J Vasc Interv Radiol; 2019 Dec; 30(12):1879-1886. PubMed ID: 31669087
[TBL] [Abstract][Full Text] [Related]
16. Prospective comparative study of different endovenous thermal ablation systems for treatment of great saphenous vein reflux.
Karathanos C; Spanos K; Batzalexis K; Nana P; Kouvelos G; Rousas N; Giannoukas AD
J Vasc Surg Venous Lymphat Disord; 2021 May; 9(3):660-668. PubMed ID: 33099037
[TBL] [Abstract][Full Text] [Related]
17. Comparison of overall survival on surgical resection versus transarterial chemoembolization with or without radiofrequency ablation in intermediate stage hepatocellular carcinoma: a propensity score matching analysis.
Lin CW; Chen YS; Lo GH; Hsu YC; Hsu CC; Wu TC; Yeh JH; Hsiao P; Hsieh PM; Lin HY; Shu CW; Hung CM
BMC Gastroenterol; 2020 Apr; 20(1):99. PubMed ID: 32272898
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic Radiofrequency Ablation for Metastatic Melanoma to the Liver.
Bale R; Schullian P; Schmuth M; Widmann G; Jaschke W; Weinlich G
Cardiovasc Intervent Radiol; 2016 Aug; 39(8):1128-35. PubMed ID: 27055850
[TBL] [Abstract][Full Text] [Related]
19. Stereotactic radiofrequency ablation as a valid first-line treatment option for hepatocellular adenomas.
Laimer G; Schullian P; Scharll Y; Putzer D; Eberle G; Oberhuber G; Bale R
Int J Hyperthermia; 2022; 39(1):780-787. PubMed ID: 35654476
[TBL] [Abstract][Full Text] [Related]
20. Health-related quality of life in patients with hepatocellular carcinoma after hepatic resection, transcatheter arterial chemoembolization, radiofrequency ablation or no treatment.
Toro A; Pulvirenti E; Palermo F; Di Carlo I
Surg Oncol; 2012 Mar; 21(1):e23-30. PubMed ID: 22104002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
